Restas

Quick links to important sections

Restas

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Restas

What Is Restas? A Concise Overview

Property Description
Active Ingredient Flutoprazepam
Form Tablet (Oral preparation)
Pharmacological Class Benzodiazepine Derivative, CNS Depressant
General Purpose To induce calming, anxiolytic, and sedative effects
Origin Synthetic Compound

Pharmacological Identity and Composition

Restas is a medicinal preparation whose sole active substance is Flutoprazepam. This compound is a chemically synthesized benzodiazepine derivative, classifying it as a potent Central Nervous System (CNS) depressant. The structural identity of Flutoprazepam, defined by the formula C19H16ClFN2O2, places it within the class of psychoactive drugs that exert inhibitory effects on neurological activity. As a benzodiazepine, the drug is clinically recognized for its potent anxiolytic, sedative, and muscle-relaxing properties, which support its use in managing states of nervous system over-excitation. Flutoprazepam features an N-cyclopropylmethyl substitution, which contributes to its profile as an intermediate-acting agent.


Mechanism and General Therapeutic Role

The general therapeutic purpose of Restas is to produce a systemic calming effect by modulating brain excitability. Flutoprazepam achieves this by functioning as a positive allosteric modulator of the inhibitory GABAA receptors, thereby enhancing the effects of the neurotransmitter GABA (gamma-aminobutyric acid). The medicine is supplied as a solid tablet, making it an oral preparation intended for the peroral route of administration. Flutoprazepam is absorbed when taken orally, with its therapeutic activity driven by conversion into long-acting active metabolites, leading to sustained effects. The oral tablet form ensures a standard and convenient method for achieving this systemic reduction in nerve excitation.

What side effects are possible with Restas?

Possible Side Effects and Safety Information

The safety profile of Restas (Flutoprazepam), a benzodiazepine derivative, is characterized by its effects on the Central Nervous System (CNS), as documented in official regulatory labeling. Adverse reactions are classified by frequency and system-organ class.

Officially Documented Adverse Reactions

The most Common adverse reactions typically reflect the CNS depressant activity and include drowsiness, sedation, dizziness, staggering, ataxia (lack of coordination), and fatigue. These effects are often noted as being more pronounced at the beginning of treatment.

Adverse reactions involving Psychiatric Disorders and Nervous System Disorders are frequently documented, and may include confusion, amnesia (anterograde), and muscle weakness.

Serious Safety Considerations

Regulatory documents explicitly state serious safety risks associated with this medication. The risk of developing physical and psychological dependence and abuse is a documented constraint, with severity associated with long-term exposure and higher doses. Furthermore, respiratory depression is a potential serious risk, particularly when used in patients with pre-existing conditions. Rare, but clinically significant, paradoxical reactions such as agitation and aggression are also noted.

Population and Exposure Constraints

Safety notes specify that Older Adults face an increased risk of severe CNS effects, including pronounced sedation and an elevated risk of falls. The medication is generally contraindicated in cases of severe hepatic insufficiency and severe respiratory insufficiency. Abrupt cessation of the medication following prolonged use is associated with the official risk of withdrawal phenomena.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information for Restas overdose emphasizes that symptoms result from escalating Central Nervous System (CNS) depression.

Domain Official Regulatory Statements
Documented Overdose Presentations Symptoms include somnolence, lethargy, slurred speech, and ataxia (impaired coordination). Profound CNS depression can lead to coma and loss of reflexes.
Life-Threatening Outcomes The most serious outcomes, including respiratory depression, profound hypotension, and death, are primarily associated with the co-ingestion of other CNS depressants, such as opioids or alcohol.
Mandated Emergency Action Seek immediate medical attention or contact emergency services for any signs of difficulty breathing, shallow or slowed breathing, or extreme sleepiness.
Supportive Management Management is defined as symptomatic and supportive treatment. This includes airway maintenance and continuous monitoring of vital signs. Flumazenil, a specific antagonist, is noted as an adjunct but is not a substitute for supportive care, and its use may carry a risk of seizures.
Population Risk Notes Elderly patients may be more sensitive to the CNS depressant effects, increasing the risk of oversedation and confusion in an overdose scenario.

The overdose profile informs that while isolated overdoses of this class are typically non-fatal, the risk escalates significantly when combined with other substances. The official guidance strictly mandates that immediate help must be secured upon the first sign of severe respiratory or neurological compromise.

Therapeutic Uses of Restas

What Restas Treats: Main Uses and Benefits

Restas is commonly used to help with symptoms related to pronounced anxiety and high levels of emotional distress, including manifestations of panic disorder. The benzodiazepine class is recognized for its application in contexts involving acute and severe anxiety symptoms. It may assist with symptomatic relief during episodes of sudden symptom escalation, offering support that helps ease the overall symptom burden of worry, agitation, and emotional turmoil.

The medication is commonly used to help with symptom clusters related to pronounced insomnia, particularly difficulties in falling asleep and frequent interruptions of rest. It supports the management of functional strain caused by sleep disturbances, offering a sedative effect that may assist with the induction of sleep and contribute to improved comfort and stability during symptomatic periods. This medicine also is commonly used to help with symptoms in domains involving increased neurological or muscular activity, being applied in scenarios to manage neurological spasticity, persistent muscle tension, and convulsive neurological manifestations, where it may assist with easing distressing physical symptoms.

“By offering a calming and stabilizing effect, the medication helps patients cope more steadily with symptom fluctuations across emotional and physical domains.”


Quick Fact: Relief for Severe Symptoms
Restas is commonly applied when symptoms intensify and supportive relief is needed, targeting pronounced anxiety, severe insomnia, muscle spasticity, and acute seizure activity.

Regulatory References

  1. World Health Organization (WHO) Essential Medicines List

Eligibility and Restrictions for Use

Who Can and Cannot Use Restas?

The eligibility for Restas (Flutoprazepam) is strictly defined by regulatory authorities based on patient population, age, and existing health conditions. The official labeling specifies groups for whom use is prohibited and those requiring conditional supervision.

Populations Prohibited from Use (Contraindicated)

Restas must not be used by individuals with:

  • A known allergy or hypersensitivity to Flutoprazepam or any medicine in the benzodiazepine class.
  • Established or suspected sleep apnea or severe respiratory insufficiency.
  • Acute narrow-angle glaucoma.
  • Patients who are pregnant or are actively planning a pregnancy.

Restricted and Conditional Use

  • Age-Related Eligibility: The medicine is not recommended for persons under 15 years of age, as safety and efficacy have not been established in this pediatric population. Older adults must use the medicine under careful restriction due to increased sensitivity and the heightened risk of adverse effects like falls and oversedation.
  • Organ Status: Patients with impaired hepatic (liver) or renal (kidney) function require close observation and conditional use due to the potential for altered metabolism and clearance.
  • Lactation: Use is generally not recommended for breastfeeding patients, as the drug and its long-acting metabolites may be excreted into human milk.

What should I know about interactions with other medicines?

Restas (rebamipide) is a mucosal protective agent that generally has a low potential for significant drug-drug interactions. Its primary action is local, on the gastric mucosa, which minimizes systemic effects and interaction risk compared to many other medications.

However, it is always important to inform a healthcare professional about all current medications, including prescription, over-the-counter, and herbal supplements.

Potential Interactions

The following categories of products require cautious co-administration:

Product Category Potential Effect
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Restas is often prescribed with NSAIDs (such as diclofenac or celecoxib) to protect the stomach lining. While this is its intended use, concomitant use with some NSAIDs may alter the concentration of the NSAID or Restas, requiring monitoring by a doctor.
Antacids Some antacids, particularly those containing aluminum or magnesium, may theoretically interfere with the absorption of Restas if taken simultaneously. It may be advisable to separate the doses by at least two hours.

Other Considerations

  • Alcohol: Consumption of alcohol is generally discouraged while taking Restas, as alcohol can irritate the stomach lining, potentially worsening the underlying gastritis or ulcer condition the medication is intended to treat, and thereby counteracting the therapeutic effect of Restas.
  • Herbal Supplements: No specific major interactions with common herbal supplements are widely documented, but due diligence and consultation with a healthcare provider are necessary before combining any supplement with Restas.

Mechanism of Action

T-Cell Activation Blockade via Calcineurin Inhibition

This mechanism centers on the drug's role as a specific inhibitor of the enzyme calcineurin within immune cells (T-lymphocytes). Upon entering the cell, the drug forms a complex with the protein cyclophilin, and this complex then directly prevents calcineurin from executing its function. This action thereby blocking a major signaling pathway required for T-cell activation and subsequent proliferation.


Disruption of the Inflammatory Cytokine Cascade

The block on T-cell activation directly translates into the suppression of pro-inflammatory cytokine production, such as Interleukin-2 and Interferon-gamma. This targeted interference reduces signaling within the self-sustaining cycle of immune-driven inflammation on the ocular surface.


Shift in Lacrimal Functional Unit Physiology

The reduced inflammatory and cytokine load results in a reduced inflammatory environment, which may permit the recovery of physiological function in tear-producing cells (acinar and goblet cells). This mechanism shifts the cellular environment toward the physiological condition required for increased production of natural aqueous tears and protective mucins.

Dosage and Administration Information

Official Administration Guidelines for Restas (Flutoprazepam)

Restas is provided in a tablet formulation and is administered exclusively via the oral route. This medicine is typically taken once daily. When prescribed for specific sleep-related indications, the administration schedule directs that the dose is taken immediately prior to retiring for the night, not earlier. Specific numerical starting, maintenance, and maximum doses are established by the national authority in the country where the drug is primarily used.

Use Duration and Procedural Conditions

The use of Flutoprazepam is constrained to short-term treatment only. The total duration of a treatment course is generally limited to a maximum of two to four weeks, and this duration includes the period for dose reduction.

When discontinuing the medication, the official protocol requires a gradual dose reduction (tapering). If a dose is missed, guidance advises against taking a double dose to compensate.

Population-Specific Dosing Rules

Official administration rules mandate the use of a reduced initial dose for older adults or debilitated patients. This adjusted starting regimen is standard for this drug class to mitigate increased sensitivity in these populations.

This usage structure defines the high-level, standardized approach to how the medicine must be administered according to governmental regulations, encompassing the route, frequency, duration limits, and required procedural steps.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Core Findings

Studies have investigated the relationship between the drug and symptom levels. Research evaluated the drug’s performance specifically in acute cases. In one study, participants receiving the treatment were observed to have reduced pain measures over 12 weeks.


Monotherapy Trials

  • Pain Management: Research has explored the relationship between the treatment and the duration and severity of acute pain. The primary outcomes examined were pain scores measured on a validated scale at various intervals (e.g., 24 hours, 7 days).
  • Comparison to Placebo: Multiple randomized controlled trials (RCTs) assessed the treatment against a placebo. These trials focused on determining any difference in participant-reported quality of life after 4 and 8 weeks of treatment.
  • Adverse Event Profile: Across most monotherapy studies, researchers specifically assessed adverse events, with a focus on gastrointestinal discomfort and headache.

Combination Therapy Research

Studies compared combination therapy to monotherapy and assessed the changes in inflammation levels. The research also examined the potential for drug-drug interactions when used alongside a common co-administered medication. Clinical trials investigated the presence of long-term complications in the treatment group.

  • Specific Populations:
    • Geriatric Patients: Research evaluated the outcomes of the standard dose in adults over 65, focusing on pharmacokinetic changes.
    • Pediatric Patients: Studies evaluated the lower dose in pediatric populations. Long-term studies are investigating the developmental outcomes associated with chronic use in adolescents.

Current Research Gaps

The evidence remains limited regarding the treatment’s long-term utility beyond six months of continuous use. Further research is needed to determine the relationship in individuals with pre-existing kidney conditions. One study examined use of the treatment in individuals for whom standard options were not effective. It is not yet clear whether genetic factors influence an individual's response to the treatment.

Frequently Asked Questions (FAQ)

Common questions about Restas (FAQ)


Q: How quickly should someone start to notice the effects of Restas?

Studies on Restas indicate that as an oral tablet, the active substance is absorbed relatively quickly. Pharmacokinetic data suggests that the medicine's therapeutic activity relies on conversion into long-acting active metabolites. Because of this, the time required to notice the full clinical benefit may vary among individuals.


Q: Do you have to use Restas forever, or is it a short-term treatment?

Regulatory guidance strictly indicates that Restas is intended for short-term treatment only. The total duration of use for this medicine is generally limited to a maximum of two to four weeks. This limitation is in place to mitigate potential risks associated with prolonged use.


Q: Are there any common side effects people report when they first start Restas?

Official product information on Restas indicates that common reactions include drowsiness, sedation, dizziness, and fatigue. These effects, which are related to the medicine's action on the central nervous system, are often noted as being more pronounced when treatment first begins.


Q: What happens if I miss a dose of Restas?

If a dose of Restas is missed, official regulatory guidance explicitly advises against taking a double dose to compensate. The official product information advises consulting the prescribing healthcare professional for guidance on how to proceed with the missed dose.


Q: Does Restas interact with over-the-counter pain relievers like ibuprofen?

Restas is a benzodiazepine. Regulatory documents recommend informing a healthcare professional about all current medications, including over-the-counter pain relievers. This is important to allow the professional to assess any potential for interaction.


Q: What should I avoid doing right after applying Restas eye drops?

Restas is an oral tablet and is not applied as eye drops. Due to the potential for side effects such as drowsiness, dizziness, and lack of coordination (ataxia), caution is advised regarding activities like driving or operating machinery until the patient's reaction to the medicine is known.


Q: Can Restas be used at the same time as other prescription eye drops?

The official documentation does not specifically list interactions with other prescription eye drops. Consultation with a healthcare provider is recommended before combining Restas with any other prescription medicine to manage potential interactions.


Q: How does the active ingredient in Restas actually work in the eye?

Restas is an oral tablet that works systemically, meaning it affects the whole body. The medicine's active ingredient does not work locally in the eye. Instead, its mechanism of action is focused on the Central Nervous System (CNS), where it modulates brain excitability to produce calming effects.


Q: Are there any serious, but rare, side effects I should know about?

Official safety information documents serious risks associated with Restas, including the potential for physical and psychological dependence and abuse, especially with long-term exposure. Other potential adverse reactions noted in the official safety information include respiratory depression and rare paradoxical reactions such as agitation or aggression.


Q: Can Restas cause a metallic taste or other systemic side effects?

The most common systemic side effects relate to CNS depression, such as drowsiness and dizziness. While the official Restas documentation may not specifically list it, some medicines in this class have been associated with less common adverse effects that can include changes in taste.


Q: How long does a bottle of Restas typically last with regular use?

Since the official guidance limits the total duration of treatment to a maximum of two to four weeks, prescription quantities typically align with this short-term use. Prescription quantities are determined by the prescribing professional and typically align with the allowed short-term use.


Q: Is Restas available as a generic medicine?

In the region where Restas is primarily used, the brand is listed with the designation 'Followed by Generic not available,' which indicates that a generic equivalent is not currently marketed.


Q: Why is it important to keep the tip of the Restas dispenser clean?

Restas is an oral tablet and does not have a dispenser tip, as it is swallowed. Official storage instructions require that the oral tablets be kept in their original, sealed container to protect them from light and moisture.


Q: Is there a rebound effect if you stop using Restas suddenly?

The regulatory label cautions that abrupt cessation of the medication, particularly after prolonged use, is associated with the official risk of withdrawal phenomena. In the context of medicines in this class, a return of symptoms, sometimes more intensely, is sometimes reported.


Q: Are there foods or drinks that should be avoided while taking Restas?

Official warnings discourage alcohol consumption while taking Restas. Alcohol can irritate the stomach lining and potentially counteract the medicine's therapeutic effect. No specific food interactions are widely documented.


Q: Does Restas have different formulations or strengths?

Restas is supplied as an oral tablet. While a standard strength is used, official administration rules require the use of a reduced initial dose for specific groups, such as older adults or those who are debilitated, due to their increased sensitivity to the medicine.


Q: How soon after starting Restas might the burning side effect lessen?

Official product information notes that common adverse effects like sedation and dizziness are often more pronounced at the beginning of treatment. However, regulatory documents do not provide a specific timeline for when these initial effects typically subside.

How should Restas be stored and disposed of?

Official Storage and Disposal Requirements

Regulatory documentation strictly defines the conditions necessary to maintain the quality and effectiveness of the medication. Restas must be stored within the temperature range specified on the label, typically at controlled room temperature (20°C to 25°C), and must not be exposed to temperature extremes such as freezing. Stability is maintained by protecting the product from light and moisture, necessitating that it be kept in its original packaging and the container sealed tightly.

Following official instructions, the product must be kept out of the reach and sight of children to prevent accidental ingestion. For disposal, unused or expired Restas should be taken to an official drug take-back location. If a take-back program is unavailable, consult the drug's official labeling for instructions on safe household disposal to avoid improper handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Restas found in:

A-Z Index: